Acceleron Pharma Inc. (XLRN) News

Acceleron Pharma Inc. (XLRN): $178.75

-0.93 (-0.52%)

POWR Rating

Component Grades








Add XLRN to Watchlist
Sign Up

Industry: Biotech




#259 of 474

in industry

Filter XLRN News Items

XLRN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

XLRN News Highlights

  • For XLRN, its 30 day story count is now at 37.
  • Over the past 28 days, the trend for XLRN's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • LAW, MRK and RARE are the most mentioned tickers in articles about XLRN.

Latest XLRN News From Around the Web

Below are the latest news stories about Acceleron Pharma Inc that investors may wish to consider to help them evaluate XLRN as an investment opportunity.

Sphinx Trading LP Takes $120,000 Position in Acceleron Pharma Inc. (NASDAQ:XLRN)

Sphinx Trading LP bought a new stake in shares of Acceleron Pharma Inc. (NASDAQ:XLRN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 700 shares of the biopharmaceutical companys stock, valued at approximately $120,000. Several other large investors also recently added to or reduced []

Dakota Financial News | November 22, 2021

Merck Closes Biggest Biotech Deal of the Year

The purchase of Acceleron Pharma gives Merck one more arrow in its quiver as it prepares for the patent on its blockbuster cancer therapeutic Keytruda to expire.

Yahoo | November 22, 2021

Merck completes tender offer for $11B Acceleron Pharma acquisition

No summary available.

Seeking Alpha | November 20, 2021

Acceleron Pharma (NASDAQ:XLRN) vs. Brickell Biotech (NASDAQ:BBI) Head to Head Comparison

Acceleron Pharma (NASDAQ:XLRN) and Brickell Biotech (NASDAQ:BBI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Insider and Institutional Ownership 90.4% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 14.2% []

Dakota Financial News | November 19, 2021

Fulton Bank N.A. Buys Shares of 1,507 Acceleron Pharma Inc. (NASDAQ:XLRN)

Fulton Bank N.A. bought a new stake in Acceleron Pharma Inc. (NASDAQ:XLRN) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,507 shares of the biopharmaceutical companys stock, valued at approximately $260,000. Other institutional investors and hedge funds have also recently made changes to []

Dakota Financial News | November 18, 2021

Merck says HSR waiting period for Acceleron Pharma deal expires

No summary available.

Seeking Alpha | November 17, 2021

Acceleron Pharma Target of Unusually Large Options Trading (NASDAQ:XLRN)

Acceleron Pharma Inc. (NASDAQ:XLRN) was the target of some unusual options trading on Wednesday. Investors acquired 14,539 call options on the company. This is an increase of 589% compared to the average volume of 2,110 call options. In other news, SVP Adam M. Veness sold 6,650 shares of the firms stock in a transaction that []

Transcript Daily | November 17, 2021

Acceleron Pharma Inc. (NASDAQ: XLRN): Dont Ditch XLRN Stock In 2021

In the latest trading session, 3.34 million Acceleron Pharma Inc. (NASDAQ:XLRN) shares changed hands as the companys beta touched 0.11. With the companys most recent per share price at $179.81 changing hands around $5.83 or 3.35% at last look, the market valuation stands at $10.64B. XLRNs current price is a discount, trading about -5.66% off Acceleron Pharma Inc. (NASDAQ: XLRN): Dont Ditch XLRN Stock In 2021 Read More »

Marketing Sentinel | November 17, 2021

These 40 Mass. companies made the new Deloitte Fast 500 list

The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.

Yahoo | November 17, 2021

Merck Is a Dividend Play Ready to Get Back in Gear

Pfizer has been beating MRK stock in 2021, but that relative performance may reverse next year, with new drugs and acquisitions ahead.

Dana Blankenhorn on InvestorPlace | November 16, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7539 seconds.